ES2135416T3 - Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv. - Google Patents

Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.

Info

Publication number
ES2135416T3
ES2135416T3 ES92922090T ES92922090T ES2135416T3 ES 2135416 T3 ES2135416 T3 ES 2135416T3 ES 92922090 T ES92922090 T ES 92922090T ES 92922090 T ES92922090 T ES 92922090T ES 2135416 T3 ES2135416 T3 ES 2135416T3
Authority
ES
Spain
Prior art keywords
piridopiridazinones
compounds
piridazinons
pde
acil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922090T
Other languages
English (en)
Inventor
Robert Stephen Wilhelm
Bradley Earl Loe
Bruce Henry Devens
Robert Alvarez
Michael Grant Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2135416T3 publication Critical patent/ES2135416T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE HA DESCUBIERTO QUE LOS COMPUESTOS DE BENZO O PIRIDOPIRIDAZINONAS Y PIRIDAZINTIONAS DE LA FORMULA (I) EN LA QUE: X E Y SON NITROGENO O CARBONO, SIEMPRE Y CUANDO AL MENOS UNO DE ELLOS SEA CARBONO Y Z ES OXIGENO O AZUFRE; R1 ES HIDROGENO, ALKILO INFERIOR, ARILO, HETEROARILO O ALKILENO INFERIOR HETEROCICLICO; R2, R3, R4, R5 Y R6 SE SELECCIONAN INDEPENDIENTEMENTE DEL HIDROGENO, ALKILO INFERIOR, HALO, CARBOXI, ALCOXICARBONILO, CARBAMILO, ACILO, HALURO DE ACILO, TIOMETILO, TRIFLUOMETILO, CIANO O NITRO; O UN ESTER, ETER O SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, SON UTILES COMO AGENTES ANTIINFLAMATORIOS, ANTIASMATICOS, INMUNOSUPERSORES, ANTI RECHAZO A LOS ALOINJERTOS, ANTI RECHAZO A LOS INJERTOS FRENTE A HUESPEDES, ENFERMEDADES AUTOINMUNES O ANALGESICOS.
ES92922090T 1991-10-09 1992-10-08 Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv. Expired - Lifetime ES2135416T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77567991A 1991-10-09 1991-10-09

Publications (1)

Publication Number Publication Date
ES2135416T3 true ES2135416T3 (es) 1999-11-01

Family

ID=25105161

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09201998A Expired - Fee Related ES2105920B1 (es) 1991-10-09 1992-10-08 Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.
ES92922090T Expired - Lifetime ES2135416T3 (es) 1991-10-09 1992-10-08 Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09201998A Expired - Fee Related ES2105920B1 (es) 1991-10-09 1992-10-08 Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.

Country Status (20)

Country Link
EP (1) EP0612321B1 (es)
JP (1) JP3245165B2 (es)
KR (1) KR100263494B1 (es)
AT (1) ATE183745T1 (es)
AU (1) AU670544B2 (es)
CA (1) CA2117059C (es)
DE (1) DE69229874T2 (es)
DK (1) DK0612321T3 (es)
ES (2) ES2105920B1 (es)
FI (1) FI108229B (es)
GR (1) GR3030969T3 (es)
HU (2) HUT66969A (es)
IL (1) IL103388A (es)
MX (1) MX9205794A (es)
NO (1) NO302888B1 (es)
NZ (1) NZ244660A (es)
PT (1) PT100938B (es)
TW (1) TW365606B (es)
WO (1) WO1993007146A1 (es)
ZA (1) ZA927755B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200689D0 (en) * 1992-01-14 1992-03-11 Rhone Poulenc Agriculture New compositions of matter
GB9314412D0 (en) * 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
WO1996006843A1 (en) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
WO1999031090A1 (en) * 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
EP0934933A1 (en) * 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
CZ20032491A3 (cs) 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty
BR0209076A (pt) 2001-04-25 2004-08-10 Altana Pharma Ag Derivados de piperazino e seu uso como inibidor de pde4
EP1385848A2 (en) * 2001-04-25 2004-02-04 ALTANA Pharma AG Phtalazinones derivatives useful as pde4/7 inhibitors
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20060166995A1 (en) * 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
BR0313330A (pt) 2002-08-10 2005-06-14 Altana Pharma Ag Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
DE602005005638T2 (de) 2004-02-04 2009-05-14 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PL383550A1 (pl) * 2007-10-15 2009-04-27 Uniwersytet Łódzki Nowe pochodne benzeno- i pirydopirydazynonów
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US11319318B2 (en) * 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
EP3428151A4 (en) * 2016-03-09 2020-02-19 Nippon Soda Co., Ltd. PYRIDINE COMPOUND AND USE THEREOF
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport
FR3105254B1 (fr) 2019-12-19 2022-08-12 Syctom Lagence Metropolitaine Des Dechets Menagers Installation et procédé de gazéification hydrothermale de biomasse
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso
KR20250033093A (ko) * 2023-08-31 2025-03-07 삼진제약주식회사 신규한 피리도 피리다진온 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2805344B2 (ja) * 1989-07-11 1998-09-30 昭和電工株式会社 オレフィン重合触媒の製造方法およびオレフィンの重合方法
JP3120857B2 (ja) * 1990-02-19 2000-12-25 中外製薬株式会社 新規な縮合複素環化合物とこれを用いた抗喘息剤

Also Published As

Publication number Publication date
NO941210L (no) 1994-04-05
JPH07500321A (ja) 1995-01-12
MX9205794A (es) 1993-04-01
EP0612321B1 (en) 1999-08-25
PT100938A (pt) 1993-10-29
ZA927755B (en) 1994-04-08
ES2105920A1 (es) 1997-10-16
AU2781592A (en) 1993-05-03
KR940702868A (ko) 1994-09-17
CA2117059A1 (en) 1993-04-15
DE69229874T2 (de) 1999-12-09
DK0612321T3 (da) 1999-12-13
CA2117059C (en) 2003-05-20
JP3245165B2 (ja) 2002-01-07
NO941210D0 (no) 1994-04-05
GR3030969T3 (en) 1999-11-30
FI108229B (fi) 2001-12-14
HU210814A9 (en) 1995-08-28
HU9400949D0 (en) 1994-06-28
IL103388A (en) 1997-09-30
AU670544B2 (en) 1996-07-25
DE69229874D1 (de) 1999-09-30
KR100263494B1 (ko) 2000-08-01
FI941567L (fi) 1994-04-06
NZ244660A (en) 1995-05-26
NO302888B1 (no) 1998-05-04
ATE183745T1 (de) 1999-09-15
PT100938B (pt) 1999-10-29
ES2105920B1 (es) 1998-07-01
HUT66969A (en) 1995-01-30
IL103388A0 (en) 1993-03-15
FI941567A0 (fi) 1994-04-06
TW365606B (en) 1999-08-01
WO1993007146A1 (en) 1993-04-15
EP0612321A1 (en) 1994-08-31

Similar Documents

Publication Publication Date Title
ES2135416T3 (es) Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
ES2036551T3 (es) Compuestos heterociclicos.
ES469952A1 (es) Un procedimiento para la preparacion de aminoalquiltiofenos
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
MY106980A (en) Heterocyclic compounds
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2065133T3 (es) Derivados de piperazina.
ATE62239T1 (de) Thiadiazin-derivate, sowie diese enthaltende pharmazeutische zusammensetzungen.
ES8500902A1 (es) Un procedimiento para la preparacion de un derivado del indol.
DE69522703D1 (de) Aminotetrazol-derivate verwendbar als stickstoff-oxid-synthase inhibitoren
ES8100280A1 (es) Un procedimiento para la preparacion de derivados de benzoxazol
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
BG101484A (bg) Използване на естери на 3-арилакрилова киселина като средства за защита от светлина и като стабилизатори на нежив органичен материал
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
MY131381A (en) Piperazine derivatives suitable for use as pharmaceuticals, in particular as 5-ht1a receptor binding agents.
ES466143A1 (es) Un procedimiento de preparacion de nuevas imidazoquinoleinas
ES474155A1 (es) Un procedimiento para la preparacion de nuevos derivados de aminoalquilfurano
ES8400440A1 (es) "procedimiento para preparar nuevas triazoloquinazolonas".
ES2032482T3 (es) Derivados del bencilidenamino-, bencilamino- y benzoilamino-imidazol y su empleo como medicamentos. (reserva del art. 167.2 cpe).
AR012553A1 (es) Una composicion que posee propiedades antivirales, en base a 7h-benz (de) antracenos y las composiciones farmaceuticas que los contienen conjuntamentecon derivados de la benzantrona
IT1216522B (it) Derivati alchiltiobenzimidazolici attivi farmacologicamente eprocedimento per la loro preparazione.
ES463162A1 (es) Procedimiento para la obtencion de derivados de 4,5-dicloro-imidazol.
ES469203A1 (es) Un procedimiento para la preparacion de benzo (c) quinolei- nas.
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612321

Country of ref document: ES